Dr. Eugene S. Lit, MD

Dr. Lit practices at East Bay Retina Consultants, Inc. in Oakland, California.

Dr. Lit's NPI, 1336132919, was assigned on August 29, 2005. Dr. Lit graduated from Harvard Medical School in 1995. Dr. Lit's California license number on file is A79215.

Dr. Lit's primary practice is East Bay Retina Consultants, Inc., at 3300 Telegraph Ave, Oakland, CA 94609-3028. The practice phone is (510) 444-1600.

Dr. Lit's primary practice is East Bay Retina Consultants, Inc. in Oakland, California. Dr. Lit is also affiliated with Alta Bates Summit Medical Center | Alta Bates Campus. Dmand AI also links Dr. Lit to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lit practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lit's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lit is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Lit has a license on file in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, eyelid inflammation, glaucoma, hereditary corneal conditions and hypertensive retinopathy among the conditions Dr. Lit treats.

CMS data shows 14,357 Medicare services from Dr. Lit across 16 procedure codes in 2024, for 1,309 Medicare patients. Medicare paid $1,652,759 for them. Every service was in an office.

CMS counts 1,309 Medicare patients who saw Dr. Lit in 2024. The largest group is 75 to 84, with 496 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 37% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lit's median patient age at 70, with 48% women.

In 2024, Dr. Lit wrote 2,997 Medicare Part D claims for 437 patients. 86% of them were for generic drugs. CMS names the drug for 2,974 of them, across 16 drugs with 11 or more claims each, at $40,775 in total drug cost. In 2023, CMS named 2,671 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lit for performance year 2024, reported as part of a group. Dr. Lit accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Lit in 2010. The most frequent topics are Vitrectomy, Diabetic Retinopathy and Feasibility Studies. Dr. Lit has published most often in Int Ophthalmol Clin. Dr. Lit's most frequent co-authors are Donald J. D'Amico, MD, John P. Cooke, MD, PhD and Diana V. Do, MD.

Dmand AI links Dr. Lit to 15 clinical trials, 8 of them phase 3 studies. Conditions studied include Retinal Vein Occlusion, Macular Degeneration and Macular Edema. Regeneron Pharmaceuticals sponsors the most, 3.

CMS Open Payments shows 5 general payments to Dr. Lit from 3 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $152.

Dmand AI lists 13 awards for Dr. Lit, most recently Margherio Award in 2002. Dr. Lit serves on Harvard Medical School Executive Selection Committee - Mead Memorial Lectureship.

Dr. Lit graduated from Harvard Medical School in 1995. Dr. Lit is a member of AAO, ASRS and CMA.

Dr. Lit is in network with 15 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.